| Bioactivity | Linzagolix (KLH-2109; OBE-2109) is a potent, non-peptide, and orally active GnRH antagonist. Linzagolix can be used for uterine fibroids, endometriosis, adenomyosis research[1]. | ||||||||||||
| Name | Linzagolix | ||||||||||||
| CAS | 935283-04-8 | ||||||||||||
| Formula | C22H15F3N2O7S | ||||||||||||
| Molar Mass | 508.42 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Susan Dababou, et al. Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas. Expert Opin Investig Drugs. 2021 Sep;30(9):903-911. |
Linzagolix
CAS: 935283-04-8 F: C22H15F3N2O7S W: 508.42
Linzagolix (KLH-2109; OBE-2109) is a potent, non-peptide, and orally active GnRH antagonist. Linzagolix can be used for
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.